Axsome Therapeutics, INC Form 4 insider transactions

Herriot Tabuteau, Chief Executive Officer, a Director and 10% owner of Axsome Therapeutics, Inc., sold 49,664 shares of common stock on August 5, 2026.

Axsome Therapeutics CEO Herriot Tabuteau executed a 10b5-1 plan transaction on July 1, 2026, involving the exercise of stock options and subsequent sale of shares.

Director Roger Jeffs sold a total of 572 shares of Axsome Therapeutics common stock to cover tax obligations related to RSU settlements.

Axsome Therapeutics Director Roger Jeffs has increased his direct ownership to 58,939 shares following the scheduled vesting of restricted stock units.

Director Mark E. Saad acquired 1,429 shares of Axsome Therapeutics following the scheduled vesting of restricted stock units.

Director Susan Mahony converted 1,429 restricted stock units and sold 600 shares to satisfy tax obligations under a pre-arranged trading plan.

Axsome Therapeutics director Mark Coleman converted 1,429 restricted stock units and sold 643 shares to satisfy tax liabilities under a Rule 10b5-1 plan.

Director Mark Coleman was granted 1,721 restricted stock units as part of his compensation package with Axsome Therapeutics.

Director Susan Mahony was granted 1,721 restricted stock units as part of Axsome Therapeutics' equity compensation program.

Axsome Therapeutics CEO Herriot Tabuteau exercised 49,670 stock options and subsequently sold the shares under a 10b5-1 plan.

Axsome Therapeutics CFO Nick Pizzie exercised 33,000 stock options and sold the resulting shares under a 10b5-1 trading plan.

Director Mark E. Saad was granted 1,721 restricted stock units as part of his compensation package with Axsome Therapeutics.

Director Roger Jeffs was granted 1,721 restricted stock units as part of an equity compensation arrangement.

Director Mark Coleman sold 17,537 shares of Axsome Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Axsome Therapeutics COO Mark Jacobson exercised and sold 4,750 shares under a pre-approved 10b5-1 trading plan.

Axsome Therapeutics COO Mark Jacobson was granted 8,669 performance stock units tied to commercial milestones.

Axsome Therapeutics CEO Herriot Tabuteau was granted 24,081 performance stock units tied to commercial milestones.

Chief Commercial Officer Ari Maizel exercised options and sold 7,500 shares of Axsome Therapeutics common stock.

Axsome Therapeutics Chief Commercial Officer Ari Maizel was granted 7,224 performance stock units tied to commercial milestones.

Axsome Therapeutics CFO Nick Pizzie was granted 8,188 performance stock units contingent upon commercial milestones.

Axsome Therapeutics General Counsel Hunter R. Murdock was granted 7,224 performance stock units tied to commercial milestones.

Axsome Therapeutics CEO Herriot Tabuteau received a grant of 54,623 Restricted Stock Units, vesting over four years.

Axsome Therapeutics' Chief Financial Officer, Nick Pizzie, was granted 18,570 restricted stock units, aligning his interests with long-term shareholder value.

Axsome Therapeutics' General Counsel, Hunter R. Murdock, received a grant of 16,385 restricted stock units.

Axsome Therapeutics' Chief Commercial Officer, Ari Maizel, received a grant of 16,385 restricted stock units, aligning executive incentives with long-term company performance.

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, was granted 19,663 restricted stock units (RSUs) on February 26, 2026, aligning executive incentives with long-term shareholder value.

Axsome Therapeutics Director Mark Coleman sold 25,000 shares of common stock for a weighted average price of $161.11, completing a pre-approved 10b5-1 trading plan.

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, exercised stock options and subsequently sold 35,378 shares of common stock for approximately $161.88 per share.

Axsome Therapeutics Director Mark Coleman exercised 6,250 stock options at $4.95 per share, increasing his direct beneficial ownership.

Axsome Therapeutics Director Mark Coleman exercised 12,485 stock options at $4.95 per share, increasing his direct beneficial ownership.